Enhertu

News

Seagen wins Enhertu patent dispute with Daiichi Sankyo

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages.

News

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potenti

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

Enhertu nabs speedy FDA review for earlier use in breast can...

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should

News

ESMO21: Enhertu brings it’s A game to second-line breast can...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r

News

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo

Seagen wins Enhertu patent dispute with Daiichi Sankyo

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

EMA starts review of Enhertu for HER2+ gastric cancer

Enhertu nabs speedy FDA review for earlier use in breast can...

ESMO21: Enhertu brings it’s A game to second-line breast can...

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

Enhertu

Editor's Picks